Comparative Pharmacology
Head-to-head clinical analysis: OXTRIPHYLLINE PEDIATRIC versus THEOPHYL 225.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXTRIPHYLLINE PEDIATRIC versus THEOPHYL 225.
OXTRIPHYLLINE PEDIATRIC vs THEOPHYL-225
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/mL.
None Documented
None Documented
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Category C
Category C
Bronchodilator
Bronchodilator